Polycythemia vera is classified as a blood cancer, but it behaves differently from most cancers you may have heard about

Polycythemia vera (PV) is a myeloproliferative neoplasm—a category of blood cancers where bone marrow produces too many blood cells. The National Cancer Institute and the World Health Organization both classify it as cancer because it involves abnormal cell growth in bone marrow that the body cannot control on its own. However, PV is not like lung cancer or breast cancer. It does not form a tumor you can see or feel, and it does not spread to other organs the way solid cancers do.

The disease starts when a mutation in a single bone marrow cell causes it to divide repeatedly. Most people with PV carry a mutation in the JAK2 gene, though some have mutations in CALR or MPL instead. This mutated cell takes over bone marrow production, flooding the bloodstream with too many red blood cells, white blood cells, or platelets. The excess cells thicken the blood and raise the risk of blood clots and stroke.

Because PV is a blood cancer, it requires ongoing medical monitoring and treatment. But the word "cancer" can mean very different things depending on the type. Understanding where PV sits on that spectrum helps you know what to expect from diagnosis, treatment, and long-term outlook.

Key Takeaways

  • Polycythemia vera is a blood cancer caused by a mutation in bone marrow cells, most often in the JAK2 gene.
  • Unlike solid cancers, PV does not form tumors or spread to other organs, and many people live for decades with the disease.
  • The main risks from PV are blood clots and stroke caused by thickened blood, not the spread of cancer cells.
  • Treatment focuses on reducing blood cell counts and preventing clots, not on killing cancer cells the way chemotherapy does for other cancers.
  • A small percentage of people with PV develop acute leukemia or scarring of the bone marrow over time, which changes the disease course.

How PV differs from solid cancers

Solid cancers like breast, lung, or colon cancer start in one location and can spread to lymph nodes, bones, or distant organs—a process called metastasis. Polycythemia vera does not work this way. It is a disease of the bone marrow itself, not a tumor that grows in one place and travels elsewhere. The problem is not that cancer cells are invading your liver or brain; the problem is that your bone marrow is making too many blood cells in the first place.

This difference matters for how doctors treat the disease. Solid cancers are often treated with surgery to remove the tumor, chemotherapy to kill cancer cells, or radiation to destroy them in a specific area. PV treatment focuses on controlling blood cell production and preventing the complications that come from too many cells—mainly blood clots. Doctors use medications like hydroxyurea or anagrelide to slow bone marrow output, or phlebotomy (removing blood) to reduce red cell counts directly.

The outlook also differs significantly. Many people with PV live 15 to 20 years or longer after diagnosis, especially if they are diagnosed before age 60. Some live into their 80s or 90s with the disease well controlled. That is not typical for most solid cancers diagnosed at an advanced stage.

Why PV is still considered cancer

Polycythemia vera meets the definition of cancer because it involves uncontrolled growth of abnormal cells in bone marrow. The cells are not responding to the body's normal signals to stop dividing. A single mutated cell has taken over production, and the body's immune system cannot stop it. That is the core feature of cancer—loss of growth control.

The classification matters for research, treatment development, and how the medical system tracks the disease. It also means that PV is taken seriously as a condition that requires treatment and monitoring, not something to ignore or manage casually. Doctors who specialize in blood cancers (hematologists and hematologic oncologists) typically manage PV because they understand how bone marrow works and how to adjust treatment as the disease changes.

However, calling PV a cancer does not mean it will behave like the cancers people fear most. The word "cancer" is an umbrella term covering hundreds of different diseases with very different outcomes, treatments, and timelines. PV sits in a category where the disease is serious and requires medical care, but many people live full lives with it.

The main health risks from polycythemia vera

The biggest danger from PV is not that cancer cells will spread through your body. The danger is that too many blood cells make your blood thicker and stickier, raising the risk of blood clots. These clots can lodge in arteries leading to the heart (causing a heart attack), the brain (causing a stroke), or the legs (causing deep vein thrombosis). Some people with PV also experience bleeding because the excess platelets do not work properly, though clotting is the more common problem.

Other complications come from the disease itself. High red cell counts can cause itching, fatigue, headaches, and a burning sensation in the hands and feet. Gout can develop because the breakdown of excess red cells releases uric acid. The spleen may enlarge as it tries to filter the excess cells. These symptoms are uncomfortable but manageable with treatment.

A smaller percentage of people—roughly 5 to 10 percent over 10 years—develop acute leukemia (a fast-growing blood cancer) or myelofibrosis (scarring of the bone marrow that makes it stop producing cells). These transformations change the disease significantly and require different treatment approaches. This risk is one reason why PV requires ongoing monitoring and why some treatments are chosen over others.

How PV is diagnosed and monitored

Polycythemia vera is usually found through a blood test that shows unusually high red cell counts, hemoglobin, or hematocrit. A doctor may order this test because you reported fatigue, headaches, or itching, or it may be discovered by chance during a routine physical. The diagnosis is confirmed by checking for the JAK2 mutation (found in about 95 percent of cases) or mutations in CALR or MPL. A bone marrow biopsy may be done to rule out other conditions and to see how much the marrow is being affected.

Once diagnosed, you will need regular blood tests—usually every few months at first, then less often once the disease is stable. These tests track your blood cell counts, kidney and liver function, and uric acid levels. Some people also need periodic bone marrow biopsies to watch for signs of transformation to leukemia or myelofibrosis, though this is not routine for everyone.

Monitoring is important because PV can change over time. A person whose disease is stable for years may eventually need a change in treatment, or the disease may transform into something more aggressive. Regular check-ins with your doctor allow treatment to be adjusted before complications develop.

Treatment options and what they target

Treatment for PV aims to reduce blood cell counts and prevent clots. The most common approach is phlebotomy—removing a unit of blood every few weeks or months to bring red cell counts down. This is simple, has few side effects, and works well for many people, especially those diagnosed before age 60 with no history of clots.

If phlebotomy alone is not enough, or if you have had a clot or are over 60, doctors add medications. Hydroxyurea is the most widely used; it slows bone marrow production and reduces the risk of clots and transformation to leukemia. Anagrelide targets platelet production specifically and is used when platelet counts are very high. Ruxolitinib, a newer drug, blocks the JAK2 pathway and can help people whose disease does not respond to other treatments or who have severe symptoms like itching or night sweats.

Low-dose aspirin is often prescribed to reduce clot risk. Some people also take allopurinol to prevent gout. The goal is not to cure PV—there is no cure except for a bone marrow transplant, which carries its own serious risks—but to keep you healthy and prevent complications for as long as possible.

Transformation and long-term disease course

Most people with PV live with a stable disease for many years. But over time, the disease can change. The most serious change is transformation to acute leukemia, which happens in about 5 to 10 percent of people over a 10-year period. This is a faster-growing cancer that requires intensive chemotherapy and has a worse outlook than PV itself.

Another change is progression to myelofibrosis, where the bone marrow becomes scarred and stops producing cells effectively. This can happen in 10 to 15 percent of people over 10 years. When this occurs, the disease becomes harder to manage because the bone marrow is no longer overproducing; instead, it is failing. Symptoms like severe fatigue, enlarged spleen, and anemia become more prominent.

The risk of these transformations is one reason why treatment choice matters. Hydroxyurea has been shown to reduce the risk of transformation compared to some other treatments, which is why it is often the first medication choice. Regular monitoring allows doctors to catch signs of transformation early, when treatment options may be more effective.

Living with a diagnosis of polycythemia vera

Being told you have cancer is frightening, even when the cancer is one like PV that many people live with for decades. It is normal to feel shocked, worried about the future, or uncertain about what comes next. But PV is not an immediate emergency for most people. You have time to learn about the disease, ask questions, and work with your doctor to build a treatment plan that fits your life.

Many people with PV work, travel, exercise, and pursue their normal activities while managing the disease. The main things you will need to do are take medications as prescribed, show up for regular blood tests, and watch for warning signs like sudden severe headaches, chest pain, or leg swelling (which could signal a clot). Some people experience fatigue or itching that affects quality of life, but these symptoms often improve with the right treatment.

Connecting with others who have PV—through support groups, online communities, or your doctor's office—can help you understand what to expect and how others manage the disease. Your hematologist or oncologist can also refer you to resources specific to myeloproliferative neoplasms.

Frequently Asked Questions

Will polycythemia vera turn into acute leukemia?

Most people with PV will not develop acute leukemia. About 5 to 10 percent of people transform to leukemia over 10 years. The risk is higher in people diagnosed at older ages or those with certain genetic markers. Regular monitoring helps catch early signs of transformation.

Can polycythemia vera be cured?

There is no cure for PV except bone marrow transplant, which carries serious risks and is rarely recommended unless the disease transforms to leukemia. Treatment focuses on controlling symptoms and preventing complications so you can live a normal lifespan.

Is polycythemia vera hereditary?

PV is not inherited. The JAK2 mutation that causes it happens randomly in a single bone marrow cell during your lifetime, not something passed down from a parent. Your children will not inherit PV, though they have the same small risk as anyone else of developing it.

How often do I need blood tests if I have polycythemia vera?

At diagnosis and during treatment changes, blood tests may be needed every few weeks. Once your disease is stable, testing usually happens every 3 to 6 months. Your doctor will tell you the schedule based on your specific situation and how well your treatment is working.

Can I work and travel with polycythemia vera?

Most people with PV work and travel without major restrictions. You should stay hydrated, avoid long periods of immobility (which raises clot risk), and keep taking your medications. Tell your employer and travel companions about the condition so they understand if you need to manage symptoms or attend medical appointments.